1798-85-2

Usage

Uses

Used in Pharmaceutical Industry:
1-Bromo-3-cyclopropylbenzene is used as an intermediate compound for the synthesis of various pharmaceutical products. Its unique structure allows it to be a key component in the development of new drugs, particularly those targeting specific biological pathways.
Used in Agrochemical Industry:
1-Bromo-3-cyclopropylbenzene is used as a starting material in the production of agrochemicals, such as pesticides and herbicides. Its chemical properties make it suitable for the creation of effective compounds that can protect crops from pests and diseases.
Used in Dye Industry:
1-Bromo-3-cyclopropylbenzene is used as a precursor in the synthesis of various dyes and pigments. Its aromatic structure contributes to the color properties of the final products, making it valuable in the creation of a wide range of colors for different applications.
However, it is important to note that 1-Bromo-3-cyclopropylbenzene may carry potential health risks due to its nature as a brominated compound. Proper handling and safety measures should be taken to minimize any adverse effects on human health and the environment.

InChI:InChI=1/C9H9Br/c10-9-3-1-2-8(6-9)7-4-5-7/h1-3,6-7H,4-5H2

Upstream product

• 2039-86-3 3-bromostyrene 
• 4109-94-8 (iodomethyl)zinc iodide 
• 52780-14-0 1-(3-bromophenyl)ethanol 
• 2142-63-4 1-(3-Bromophenyl)ethanone 
• 75-11-6 diiodomethane 
• 1372474-95-7 sodium 3-(N-methyl-N-nitrososulfamoyl)benzoate 

Downstream Products

• 1129-06-2 3-cyclopropylbenzoic acid 
• 19936-13-1 (3-Cyclopropyl-phenyl)-dimethyl-carbinol 
• 945717-15-7 (4-tert-butylbenzyl)-[2-(3-cyclopropylphenyl)-ethyl]-amine 
• 97985-66-5 3-(3-bromophenyl)prop-2-en-1-al 
• 1075178-25-4 3-(3-bromophenyl)-3-hydroxypropanenitrile 
• 1049730-10-0 3-(cyclopropylphenyl)boronic acid 
• 1632197-03-5 C₂₇H₂₇Bi 

Relevant academic research and scientific papers

Silylium-Ion-Promoted Ring-Opening Hydrosilylation and Disilylation of Unactivated Cyclopropanes

A silylium-ion-promoted ring-opening hydrosilylation of unactivated cyclopropanes is reported. The reaction is facilitated by the γ-silicon effect, and the regioselectivity is influenced by various stabilizing effects on the carbenium-ion intermediates, including the β-silicon effect. The experimental observations are in accord with the computed reaction mechanism. The work also showcases the ability of silylium ions to isomerize cyclopropyl to allyl groups, and the resulting α-olefins engage in a silylium-ion-mediated disilylation with hexamethyldisilane.

Iron-catalyzed cyclopropanation in 6 M KOH with in situ generation of diazomethane

Diazomethane is a common and versatile reagent in organic synthesis whose broader use is generally impeded by its explosiveness and toxicity. Here we report that a simple iron porphyrin complex catalyzes the cyclopropanation of styrenes, enynes, and dienes under the demanding conditions [aqueous 6 molar potassium hydroxide (KOH) solution, open to air] necessary for the in situ generation of diazomethane from a water-soluble diazald derivative. A biphasic reaction medium arising from the immiscibility of the olefin substrates with water appears essential to the overall efficiency of the process. The work we describe highlights an approach to catalysis with untoward reactive intermediates, in which the conditions for their generation under operationally safe regimes dictate catalyst selection.

4-PHENYL-PYRIMIDINE-2-CARBONITRILE DERIVATIVES

The invention relates to 4-phenyl-pyrimidine-2-carbonitrile derivatives having the general formula (I) or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising said derivatives as well as to the use thereof in the preparation of a medicament suitable for the treatment of osteoporosis, atherosclerosis, inflammation and immune disorders, such as rheumatoid arthritis, and chronic pain, such as neuropathic pain.

NEW COMPOUNDS

The present invention relates to new compounds of formula I, (I) a process for their preparation and new intermediates prepared therein, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.

NITROGENOUS FUSED?RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF

The present invention provides a compound having an excellent inhibitory action on activation of STAT6 and a pharmaceutical composition thereof. Inparticular, it provides a compound represented by the following formula (I), a salt thereof or a hydrate of them. In the formula, X represents a nitrogen-containing condensed aromatic heterocyclic group such as imidazo[1,2-a]pyridine, benzimidazole, quinazoline, quinoline, or 2,1-benzisoxazole and has (R4)n as substituent groups; Y represents a C3-8 cycloalkyl group, C4-8 cycloalkenyl group, 5- to 14-membered non-aromatic heterocyclic group, C6-14 aromatic hydrocarbon cyclic group or 5- to 14-membered aromatic heterocyclic group; n in (R4)n is 0, 1, 2 or 3, and Z groups independently represent (1) hydrogen atom, (2) amino group, (3) halogen atom, (4) hydroxyl group, (5) nitro group, (6) cyano group, (7) azido group, (8) formyl group, (9) hydroxyamino group, (10) sulfamoyl group, (11) guanodino group, (12) oxo group, (13) C2-6 alkenyl group, (14) C1-6 alkoxy group, (15) C1-6 alkylhydroxyamino group, (16) halogenated C1-6 alkyl group, (17) halogenated C2-6 alkenyl group, (18) (i) C3-7cycloalkyl group, (ii) C3-7cycloalkenyl group, (iii) 5- to 14-membered non-aromatic heterocyclic group, each of which may have one or more substituent groups Q, or (19) formula -M1-M2-M3, R1 represents (1) hydrogen atom, (2) halogen atom, (3) hydroxyl group, (4) nitro group, (5) cyano group, (6) halogenated C1-6 alkyl group, (7) C2-6 alkyl group substituted with a hydroxyl or cyano group, (8) C2-6 alkenyl group, or (9) formula -L1-L2-L3, and R2 represents a hydrogen atom or a protecting group; and R3 represents a hydrogen atom, halogen atom, cyano group, amino group, C1-4 alkyl group or halogenated C1-4 alkyl group.